US20200000745A1 - Chemical medicinal composition used for the improvement of sleep - Google Patents

Chemical medicinal composition used for the improvement of sleep Download PDF

Info

Publication number
US20200000745A1
US20200000745A1 US15/972,192 US201815972192A US2020000745A1 US 20200000745 A1 US20200000745 A1 US 20200000745A1 US 201815972192 A US201815972192 A US 201815972192A US 2020000745 A1 US2020000745 A1 US 2020000745A1
Authority
US
United States
Prior art keywords
sleep
medicinal composition
improvement
chemical
composition used
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/972,192
Inventor
Kimberly Denise Wesley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US15/972,192 priority Critical patent/US20200000745A1/en
Publication of US20200000745A1 publication Critical patent/US20200000745A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Definitions

  • the chemical compound used for sleeplessness does not require a physicians prescription and is non-habit forming.
  • a method for treating insomnia characterized by difficulties with sleep maintenance comprises administering a dosage of the chemical medicinal composition of C 30 H 38 CINO 3 or a pharmaceutically acceptable salt thereof to a patient having a sleep disorder in which, for a given eight-hour period of desired sleep, the patient experiences interrupted sleep during the first 60 minutes of initial sleep.
  • the desired dose is between 6 mg and 15 mg of the chemical or medicinal composition of C 30 H 38 CINO 3 or a pharmaceutically acceptable salt given prior to the start of sleep.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The compounds are of the class of antioxidant biogenic amines and a class of ethanolamines that are used to treat short-term insomnia by promoting sleep onset and maintenance.

Description

  • A medicinal preparation to alleviate sleeplessness using the molecular formula;

  • C30H38CINO3
  • The chemical compound used for sleeplessness does not require a physicians prescription and is non-habit forming.
  • A method for treating insomnia characterized by difficulties with sleep maintenance, the method comprises administering a dosage of the chemical medicinal composition of C30H38CINO3 or a pharmaceutically acceptable salt thereof to a patient having a sleep disorder in which, for a given eight-hour period of desired sleep, the patient experiences interrupted sleep during the first 60 minutes of initial sleep. the desired dose is between 6 mg and 15 mg of the chemical or medicinal composition of C30H38CINO3 or a pharmaceutically acceptable salt given prior to the start of sleep.

Claims (1)

1. A method for treating insomnia characterized by difficulties with sleep maintenance, wherein the method comprises administering a dosage of the chemical medicinal composition of C30H38CINO3 or a pharmaceutically acceptable salt thereof to a patient having a sleep disorder in which, for a given eight-hour period of desired sleep, the patient experiences interrupted sleep during the first 60 minutes of initial sleep. the desired dose is between 6 mg and 15 mg of the chemical or medicinal composition of C30H38CINO3 or a pharmaceutically acceptable salt given prior to the start of sleep.
US15/972,192 2018-07-02 2018-07-02 Chemical medicinal composition used for the improvement of sleep Abandoned US20200000745A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/972,192 US20200000745A1 (en) 2018-07-02 2018-07-02 Chemical medicinal composition used for the improvement of sleep

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15/972,192 US20200000745A1 (en) 2018-07-02 2018-07-02 Chemical medicinal composition used for the improvement of sleep

Publications (1)

Publication Number Publication Date
US20200000745A1 true US20200000745A1 (en) 2020-01-02

Family

ID=69054555

Family Applications (1)

Application Number Title Priority Date Filing Date
US15/972,192 Abandoned US20200000745A1 (en) 2018-07-02 2018-07-02 Chemical medicinal composition used for the improvement of sleep

Country Status (1)

Country Link
US (1) US20200000745A1 (en)

Similar Documents

Publication Publication Date Title
FI3307271T3 (en) Methods of using pyruvate kinase activators
HK1104968A1 (en) Use of immunomodulatory compounds in the manufacture of a medicament for the treatment and management of cancers and other diseases, and compositions thereof
MX2022003072A (en) Use of pridopidine for treating functional decline.
MXPA05012155A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases.
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
RU2017134443A (en) METHOD OF TREATMENT WITH USE OF TRADIPTANT
RU2013148721A (en) COMBINATIONS OF COMPOUNDS INHIBITING ACT AND VEMURAFENIBA AND WAYS OF THEIR APPLICATION
MX2021008247A (en) Combination of dextromethorphan and bupropion for treating depression.
JP2018507243A5 (en)
MX2010003556A (en) Treatment regime for proliferative disorders.
HK1071310A1 (en) Combination therapy for the treatment of cancer
MX2022015629A (en) Use of vibegron to treat overactive bladder.
RU2012108656A (en) APPLICATION OF 4-AMINOPYRIDINE TO IMPROVE CONDITION IN NEURO-COGNITIVE AND / OR NEUROPSYCHIATRIC DISORDERS IN PATIENTS WITH DEMILINIZING AND OTHER DISEASES OF THE NERVOUS SYSTEM
PE20221338A1 (en) METHODS OF TREATMENT OF SMALL CELL LUNG CANCER WITH FORMULATIONS OF LURBINECTEDIN
JP2016509050A5 (en)
NZ751972A (en) Treatment of prurigo nodularis
ZA201905212B (en) Rescue treatment of post operative nausea and vomiting
MX2013003523A (en) Low dose pharmaceutical composition comprising zanamivir.
MX2022006083A (en) Methods of treating conditions related to the s1p1 receptor.
BRPI0508983A (en) use of azd2171 or a pharmaceutically acceptable salt thereof excluding an azd2171 maleate salt and a taxane, pharmaceutical composition, kit, and method for producing antiangiogenic effect and / or reducing vascular permeability in a warm-blooded animal such as as a human being
MX2021008986A (en) Methods of treating a patient having parkinson's disease.
US20200000745A1 (en) Chemical medicinal composition used for the improvement of sleep
CA2531620A1 (en) Cancer combination therapy comprising azd2171 and zd1839
MX2010006310A (en) O-desmethyl-venlafaxine for treating major depressive disorder.
MX2021007324A (en) Oral therapy using 6,8-bis-benzylthio-octanoic acid.

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION